Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03597620 · ClinicalTrials.gov registry record · Phase 4
Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT03597620 is a Phase 4 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 11 participants.
The verdict
NCT03597620, a Phase 4 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
Psoriasis vulgaris is a common inflammatory condition of the skin that results in well-demarcated, scaly, erythematous, itchy plaques. In the United States, psoriasis remains a common, immune-mediated disease, affecting 7.4 million adults. Often topical prescription medications are used as first line treatment for moderate psoriasis. Some topical medications have side effects and risk with long time use, thus not ideal for extensive and indefinite amount of time. Conversely, over- the-counter emollient treatments are readily available, safe and potentially efficacious. This study is design to test the safety and efficacy of topical application of the Metaderm product cream. The Metaderm cream is non-prescription, natural product.
Interventions
- DRUG Metaderm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-11-07 |
| Est. Completion | 2022-12-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03597620
The ClinicalTrials.gov registry entry for NCT03597620 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metaderm is the first listed.
NCT03597620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03597620 about?
NCT03597620 is a clinical study titled "Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis". Psoriasis vulgaris is a common inflammatory condition of the skin that results in well-demarcated, scaly, erythematous, itchy plaques. In the United States, psoriasis remains a common, immune-mediated disease, affecting 7.4 million adults. Often topical prescription medications are used as first lin...
What is the current status of trial NCT03597620?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2018-11-07. Estimated completion is 2022-12-13.
What interventions are being tested in trial NCT03597620?
The interventions under investigation include: Metaderm (DRUG).
Who is sponsoring clinical trial NCT03597620?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.